Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 4CNS 2

Conditions

Neuroblastoma 2Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Cefixime × CNS × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00644696 2017-07-06

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

University of Michigan Rogel Cancer Center

Phase 1 Completed
18 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡